Clinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinoma.
Early liver spread predicts which advanced kidney cancer patients won't respond to modern immunotherapy plus anti-angiogenic drugs.
This first integrated clinical and genomic characterization of primary resistance to IO+VEGFR therapy in mRCC used a dual-cohort approach combining a real-world H-CARP registry (n=159) with Japan's national C-CAT genomic database. PRD patients faced a median OS of only 8.5 months with no benefit from subsequent therapies; liver metastasis emerged as an accessible early predictor, and hypothesis-generating genomic correlates (TSC2/MSH3 enrichment) require prospective validation.
What the study was
- Study design
- Retrospective cohort study with national genomic database validation (H-CARP + C-CAT)
- Population
- Metastatic renal cell carcinoma patients receiving IO+VEGFR first-line therapy (H-CARP real-world registry n=159 + Japanese C-CAT national genomic database)
- Sample size
- 159
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Scientific reports
Why it surfaced
Sci Rep; first integrated clinical+genomic characterization of mRCC primary resistance to IO+VEGFR; H-CARP+C-CAT dual cohort; liver metastasis as accessible early PRD predictor; matched via 'unmet need' query; critical unmet need for 12.6% of mRCC patients.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.